Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study von de Vos, S., Swinnen, L.J., Wang, D., Reid, E., Fowler, N., Cordero, J., Dunbar, M., Enschede, S.H., Nolan, C., Petrich, A.M., Ross, J.A., Salem, A.H., Verdugo, M., Agarwal, S., Zhou, L., Kozloff, M., Nastoupil, L.J., Flowers, C.R.

Volltext